Monoclonal antibodies are a growing class of targeted cancer therapeutics, characterized by
exquisite specificity, long serum half-life, high affinity and immune effector functions. In this …

Immunoglobulin A (IgA) plays a key role in defending mucosal surfaces against attack by
infectious microorganisms. Such sites present a major site of susceptibility due to their vast …

Immuno‐oncology is revolutionizing the treatment of cancers, by inducing the recognition
and elimination of tumor cells by the immune system. Recent advances have focused on …

Success with B cell depletion using rituximab has proven the concept that B lineage cells
represent a valid target for the treatment of autoimmune diseases, and has promoted the …

Monoclonal antibodies (mAbs) targeting human antigen CD20 (cluster of differentiation 20)
constitute important immunotherapies for the treatment of B cell malignancies and …

Cluster of differentiation 20 (CD20) is a B cell membrane protein that is targeted by
monoclonal antibodies for the treatment of malignancies and autoimmune disorders but …

There have been major advances in the immunotherapy of cancer in recent years, including
the development of T cell engagers—antibodies engineered to redirect T cells to recognize …

Cancer and autoimmune disease are closely related, and many therapeutic antibodies are
widely used in clinics for the treatment of both diseases. Among them, the anti-CD20 …

The diagnosis of autoimmune hemolytic anemia (AIHA) can be made with a stepwise
approach that aims to identify laboratory and clinical evidence of hemolysis and then …

Unconjugated anti-cancer IgG1 monoclonal antibodies (mAbs) activate antibody-dependent
cellular cytotoxicity (ADCC) by natural killer (NK) cells and antibody-dependent cellular …